Evidence map›Paper›PMID 42283327›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026

Operationalizing diffusion magnetic resonance imaging positivity for detection of vascular contributions to impairment and dementia.

Mingzhao Hu, Scott A Przybelski, Terry M Therneau, Emily S Lundt, Heather J Wiste, Carly T Mester, Michael Kamykowski, Robert I Reid, Mary M Machulda, David S Knopman and 4 more

Abstract read
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Mingzhao HuDepartment of Quantitative Health Sciences Division of Clinical Trials and Biostatistics, Mayo Clinic-Rochester, Rochester, Minnesota, USA.
Scott A PrzybelskiDepartment of Quantitative Health Sciences Division of Clinical Trials and Biostatistics, Mayo Clinic-Rochester, Rochester, Minnesota, USA.
Terry M TherneauDepartment of Quantitative Health Sciences Division of Clinical Trials and Biostatistics, Mayo Clinic-Rochester, Rochester, Minnesota, USA.
Emily S LundtDepartment of Quantitative Health Sciences Division of Clinical Trials and Biostatistics, Mayo Clinic-Rochester, Rochester, Minnesota, USA.
Heather J WisteDepartment of Quantitative Health Sciences Division of Clinical Trials and Biostatistics, Mayo Clinic-Rochester, Rochester, Minnesota, USA.
Carly T MesterDepartment of Quantitative Health Sciences Division of Clinical Trials and Biostatistics, Mayo Clinic-Rochester, Rochester, Minnesota, USA.
Michael KamykowskiDepartment of Information Technology, Mayo Clinic-Rochester, Rochester, Minnesota, USA.
Robert I ReidDepartment of Information Technology, Mayo Clinic-Rochester, Rochester, Minnesota, USA.
Mary M MachuldaDepartment of Psychiatry & Psychology, Mayo Clinic-Rochester, Rochester, Minnesota, USA.
David S KnopmanDepartment of Neurology, Mayo Clinic-Rochester, Rochester, Minnesota, USA.
Ronald C PetersenDepartment of Neurology, Mayo Clinic-Rochester, Rochester, Minnesota, USA.
Clifford R JackDepartment of Radiology, Mayo Clinic-Rochester, Rochester, Minnesota, USA.
Jonathan Graff-RadfordDepartment of Neurology, Mayo Clinic-Rochester, Rochester, Minnesota, USA.
Prashanthi VemuriDepartment of Radiology, Mayo Clinic-Rochester, Rochester, Minnesota, USA.

Funding

SUPPLEMENT TO ALZHEIMERS DISEASE PATIENT REGISTRYU01AG006786 · NIA · MAYO CLINIC ROCHESTER · PI GRAFF-RADFORD, JONATHAN, JACK, CLIFFORD R. · 1986 to 2023
$49.6M
THE PGRN/TDP-43 AXIS IN ALZHEIMER?S DISEASE AND NEURODEGENERATIONP50AG016574 · NIA · MAYO CLINIC ROCHESTER · PI PETERSEN, RONALD C · 1999 to 2018
$36.9M
Investigating Resistance and Resilience Mechanisms in Alzheimer’s DiseaseR01AG056366 · NIA · MAYO CLINIC ROCHESTER · PI PRASHANTHI VEMURI · 2017 to 2026
$7.0M
Disease pathways in the population determined by amyloid, tau, and neurodegeneration imaging biomarkersR37AG011378 · NIA · MAYO CLINIC ROCHESTER · PI CLIFFORD R. JACK · 2018 to 2026
$6.8M
MarkVCID Validation in the General CommunityUF1NS125417 · NINDS · MAYO CLINIC ROCHESTER · PI PETERSEN, RONALD C, VEMURI, PRASHANTHI · 2021 to 2023
$6.1M
"What is N?" Towards operationalizing neurodegeneration in Alzheimer's and related dementiasRF1AG069052 · NIA · MAYO CLINIC ROCHESTER · PI GRAFF-RADFORD, JONATHAN, MIELKE, MICHELLE M · 2021 to 2021
$2.4M
GHR FoundationNIH HHS P50 AG016574NIH HHS R01 AG056366NIH HHS R37 AG011378NIH HHS RF1 AG069052NIH HHS U01 AG006786NIH HHS UF1 NS125417
6 · The paper itself

Abstract

introductionWhite matter lesions on fluid-attenuated inversion recovery magnetic resonance imaging (FLAIR-MRI) reflect small vessel disease (SVD) and aid in identifying vascular contributions to impairment and dementia (VCID). Emerging diffusion MRI (dMRI) biomarkers are sensitive to early SVD but the lack of validated approaches for defining dMRI abnormality has limited their clinical utility.

methodsIn 3934 participants (8749 observations) from a population-based sample, we classified 9% as vascular cognitive impairment versus not (VCI+/VCI-) using abnormal FLAIR-MRI and cognitive testing. We evaluated four distinct dMRI positivity criteria and assessed performance in an independent clinical sample.

resultsThe young referent criterion performed best and yielded an estimated prevalence of dMRI positivity aligned with pathology literature. About 40% of the population were dMRI positive, and these individuals had lower baseline cognition and faster longitudinal decline. Cutpoints were validated in an independent clinical sample. DISCUSSION: The proposed dMRI abnormality framework can detect VCID and aid in identification of individuals at risk of VCI.

Indexed as

Cognitive DysfunctionDementia, VascularDiffusion Magnetic Resonance ImagingWhite MatterAgedBrainFemaleHumansMaleMiddle Agedcutpointsdiffusion MRIearly white matter changesrisk of cognitive declineVCID

Identifiers

PMID42283327
PMCPMC13261687

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.